PM 8003
Alternative Names: PM-8003Latest Information Update: 19 Dec 2023
At a glance
- Originator Biotheus
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2023 Discontinued - Phase-I for Cancer in China (Parenteral)
- 24 Sep 2021 Phase-I clinical trials in Cancer in China (Parenteral) (Biotheus website, September 2021)
- 27 Aug 2020 Preclinical trials in Cancer in China (Parenteral), prior to August 2020 (Biotheus pipeline, August 2020)